Bigfoot Biomedical

Real-World Data Demonstrate the Potential for Rapid and Durable Improvement in Glycemic Control for People with Insulin-requiring Diabetes Using the Bigfoot Unity® System

Retrieved on: 
Wednesday, June 21, 2023
Research, Medical Devices, FDA, Diabetes, Clinical Trials, Biotechnology, General Health, Health, Science, Other Science, CGM, Injection, Insulin, Bigfoot Biomedical, GMI, PC, Biomedicine, Patient, Manuscript, American Diabetes Association, Bigfoot, ADA, Pharmaceutical industry, Dietary supplement, MD, System, Glycated hemoglobin

In this initial 58-person cohort, results demonstrate the potential of the Bigfoot Unity System to support rapid and durable improvement in glucose control in people with diabetes who use multiple daily injections of insulin.

Key Points: 
  • In this initial 58-person cohort, results demonstrate the potential of the Bigfoot Unity System to support rapid and durable improvement in glucose control in people with diabetes who use multiple daily injections of insulin.
  • The retrospective analysis initially looked at 75 Bigfoot Unity System users across 13 clinics who had used the system for six months.
  • The average age of participants included in the analysis was 62 years old, and 84.5 percent had type 2 diabetes.
  • Per the prespecified outcomes analysis, glucose management indicator (GMI) was used as a proxy for HbA1c after patients started using the System.

Bigfoot Biomedical Acquires Reinforcement Learning Algorithm for Insulin Titration Developed at McGill University

Retrieved on: 
Thursday, March 30, 2023
Research, Medical Devices, Diabetes, Clinical Trials, Health Technology, Biometrics, Health, Pharmaceutical, Science, CGM, Insulin, Bigfoot Biomedical, Workflow, Type 2 diabetes, Multimedia, Biomedical engineering, Associate, HCP, Acquisition, Biomedicine, Patient, McGill University, Bigfoot, FDA, Medicine, Pharmaceutical industry

Bigfoot Biomedical (Bigfoot), a leader in developing intelligent connected injection support systems, today announced the acquisition of a reinforcement learning algorithm for the titration of insulin settings developed at McGill University .

Key Points: 
  • Bigfoot Biomedical (Bigfoot), a leader in developing intelligent connected injection support systems, today announced the acquisition of a reinforcement learning algorithm for the titration of insulin settings developed at McGill University .
  • The algorithm is designed to observe how well people with insulin-requiring diabetes respond to a particular insulin dose, and provide a recommended adjustment based on their body’s response.
  • View the full release here: https://www.businesswire.com/news/home/20230330005190/en/
    Bigfoot Biomedical Acquires Reinforcement Learning Algorithm for Insulin Titration Developed at McGill University (Graphic: Business Wire)
    McGill University conducted an in-silico retrospective study that applied the university’s algorithm to Bigfoot Unity user data from 20 patients to evaluate the algorithm’s ability to predict appropriate insulin dosing adjustments.
  • “The retrospective study performed by the McGill University team demonstrates strong promise for the algorithm’s ability to help further simplify diabetes management,” said Jeffrey Brewer, CEO of Bigfoot Biomedical.

Bigfoot Biomedical Named to Fast Company’s “World’s Most Innovative Companies” List

Retrieved on: 
Thursday, March 9, 2023
Apps, Applications, Technology, Medical Devices, Medical Supplies, Diabetes, Health Technology, Biometrics, Health, General Health, Insulin, Early stage innovation company, NASA, MDI, Bigfoot Biomedical, Biomedicine, Creativity, MrBeast, Injection, Suggestion, Bigfoot, FDA, Organization, CGM, Pharmaceutical industry

Bigfoot Biomedical (Bigfoot), a leader in developing intelligent connected injection support systems, has been selected as one of Fast Company's 2023 “ World’s Most Innovative Companies ” in the medical device category.

Key Points: 
  • Bigfoot Biomedical (Bigfoot), a leader in developing intelligent connected injection support systems, has been selected as one of Fast Company's 2023 “ World’s Most Innovative Companies ” in the medical device category.
  • Fast Company is the world’s leading business media brand, with an editorial focus on innovation in technology, leadership, world changing ideas, creativity, and design.
  • “What a strange and thrilling year it has been to honor this year’s Most Innovative Companies.
  • Everyone on this list does something completely, uniquely different, yet, they all have one thing in common: innovation,” said Fast Company editor-in-chief Brendan Vaughan.

Bigfoot Biomedical Receives FDA Clearance for Bigfoot Unity® Android App for People Living with Insulin-Requiring Diabetes

Retrieved on: 
Thursday, March 2, 2023
Biometrics, General Health, Health, FDA, Diabetes, Health Technology, Technology, Apps, Applications, Multimedia, Mobile app, Android, Google Play, IOS, CGM, Biomedicine, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Bigfoot Biomedical, Food, Smartphone, Medical device

Bigfoot Biomedical (Bigfoot), a leader in developing intelligent connected injection support systems, today announced the U.S. Food and Drug Administration (FDA) has issued 510(k) clearance for the Android version of the Bigfoot Unity® Mobile App, a necessary component of the Bigfoot Unity® Diabetes Management System.

Key Points: 
  • Bigfoot Biomedical (Bigfoot), a leader in developing intelligent connected injection support systems, today announced the U.S. Food and Drug Administration (FDA) has issued 510(k) clearance for the Android version of the Bigfoot Unity® Mobile App, a necessary component of the Bigfoot Unity® Diabetes Management System.
  • Given that 41 percent of U.S. smartphone users choose Android devices1, this clearance enables expanded access to a large group of people with diabetes.
  • Bigfoot Unity has been compatible with iOS devices since May 2021.
  • Those interested in staying apprised of Bigfoot’s Android app updates can fill out this form .

Insulet Acquires Insulin Pump Patents from Bigfoot Biomedical as Both Companies Prioritize Improved Insulin Delivery Technologies

Retrieved on: 
Monday, February 13, 2023
Biotechnology, Diabetes, Medical Devices, Health, Pharmaceutical, Bigfoot Biomedical, CGM, AID, Construction Research and Innovation Strategy Panel, Insulin, Bigfoot, Acquisition, Research, Digital Production Partnership, IP, Corporation, Medical device, Pharmaceutical industry

Insulet Corporation (NASDAQ: PODD) (Insulet), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, and Bigfoot Biomedical (Bigfoot), a leader in developing intelligent connected injection support systems, today announced Insulet has acquired assets related to Bigfoot’s pump-based automated insulin delivery (AID) technologies.

Key Points: 
  • Insulet Corporation (NASDAQ: PODD) (Insulet), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, and Bigfoot Biomedical (Bigfoot), a leader in developing intelligent connected injection support systems, today announced Insulet has acquired assets related to Bigfoot’s pump-based automated insulin delivery (AID) technologies.
  • Insulet paid $25M for the acquisition, which includes certain Bigfoot patents related to pumps that may be used for AID therapy.
  • The transaction further strengthens Insulet’s intellectual property (IP) portfolio and provides Bigfoot with additional capital to expand its Bigfoot Unity® Diabetes Management System to more people in need of connected insulin injection support technologies.
  • Different types of insulin delivery technologies are built to address the varying needs of people with diabetes.

Bigfoot Biomedical Announces Insulin Compatibility Expansion to Support Insulin Affordability and Flexibility for People with Diabetes

Retrieved on: 
Monday, November 7, 2022
Biotechnology, Insurance, Pharmaceutical, Health, Diabetes, Medical Devices, Professional Services, Health Insurance, Insulin, Medicare, Biomedicine, Bigfoot Biomedical, FDA, Bigfoot, Population, NYSE, Medicaid, Insulin aspart, CEO, Walmart, Novo Nordisk, CGM, Diabetes, NVO, Technology, Club, Insurance, American Diabetes Association, Pharmaceutical industry, Facebook, Lilly, Insulin lispro

It is a critical part of our mission, said Jeffrey Brewer, CEO of Bigfoot Biomedical.

Key Points: 
  • It is a critical part of our mission, said Jeffrey Brewer, CEO of Bigfoot Biomedical.
  • Our expansion of compatibility to include additional insulin brands will make it easier for Bigfoot to support a broader population of people with insulin-requiring diabetes and will give Bigfoot Unity users greater flexibility to switch between insulin brands when they have a change in insurance.
  • This news marks an important moment in time for Bigfoot as we strive to make insulin diabetes management tools more accessible for people who need them.
  • Bigfoot Biomedical was founded by a team of people with personal connections to Type 1 and Type 2 diabetes.

Global Smart Insulin Pens Market Report 2022-2026 & 2031 Featuring Key Players - Eli Lilly and Company; Novo Nordisk A/S; Diamesco Co. Ltd.; Emperra GmbH E-Health Technologies - ResearchAndMarkets.com

Retrieved on: 
Monday, September 12, 2022
Diabetes, Health Technology, Health, Medical Devices, Blood, FDA, Smartphone, Association, Population, Company, USB, Insulin, Partnership, Abbott, Diabetes, Dexcom, Patient, Bigfoot Biomedical, CGM, G6, Novo Nordisk, Hospital, Eli Lilly and Company, A1C, Medical device, Pharmaceutical industry, Glooko, Lilly

The smart insulin pens market consists of sales of smart insulin pens which allows to dial the insulin dose accurately and related products.

Key Points: 
  • The smart insulin pens market consists of sales of smart insulin pens which allows to dial the insulin dose accurately and related products.
  • The smart insulin pens are injector pens with the needle that help people with diabetes to manage insulin delivery.
  • The main types of smart insulin pens are first-generation pens and second-generation pens (Bluetooth enabled, USB connected).
  • The second-generation smart insulin pens are devices that are engineered with Bluetooth or USB features to enable closer monitoring.

Bigfoot Unity® Demonstrates Strong Glycemic Control Among People with Type 2 Diabetes in Real-World Retrospective Analysis

Retrieved on: 
Sunday, June 5, 2022
Technology, Research, Medical Devices, Diabetes, Software, Health, Pharmaceutical, Data Management, Science, Time, Biomedicine, American Diabetes Association, LinkedIn, CGM, GMI, MDI, Type 2 diabetes, Diabetes, Solution, Bigfoot, Bigfoot Biomedical, FDA, Patient, Glycated hemoglobin, Insulin, PC, Twitter, Population, Instagram, Pharmaceutical industry, Medical device, Facebook, MD

Data from the real-world retrospective analysis suggests that, for people on multiple daily injections (MDI) of insulin, using the Bigfoot Unity System has the potential for rapid and durable improvement in glycemic control.

Key Points: 
  • Data from the real-world retrospective analysis suggests that, for people on multiple daily injections (MDI) of insulin, using the Bigfoot Unity System has the potential for rapid and durable improvement in glycemic control.
  • The First Real-World Experience with Bigfoot Unity A 3-Month Retrospective Analysis analyzed 49 people with diabetes with an average age of 60.3 years.
  • The study found strong glucose control at three months of use of Bigfoot Unity.
  • Bigfoot Biomedical was founded by a team of people with personal connections to Type 1 and Type 2 diabetes.

Bigfoot Biomedical Announces Late-Breaking Poster Presentation and Product Theater at the 2022 American Diabetes Association 82nd Scientific Sessions

Retrieved on: 
Wednesday, June 1, 2022
Health, Diabetes, Biomedicine, Type 1, ADA, LinkedIn, American Diabetes Association, CEO, MDI, Type 2 diabetes, Solution, Bigfoot, Bigfoot Biomedical, FDA, Insulin, Diabetes, GlySens ICGM, AM, Tulane University, Twitter, Type 2, Instagram, Medical device, Pharmaceutical industry, Facebook, MD, Pharmacology

Bigfoot Biomedical , a mission-driven company dedicated to supporting better health outcomes for people with insulin-requiring diabetes, today announced late-breaking presentation of The First Real World Experience with Bigfoot Unity: A 3-Month Retrospective Analysis at the 2022 American Diabetes Association (ADA) 82nd Scientific Sessions .

Key Points: 
  • Bigfoot Biomedical , a mission-driven company dedicated to supporting better health outcomes for people with insulin-requiring diabetes, today announced late-breaking presentation of The First Real World Experience with Bigfoot Unity: A 3-Month Retrospective Analysis at the 2022 American Diabetes Association (ADA) 82nd Scientific Sessions .
  • "We are excited to deliver critical diabetes innovation and present our first real-world data during ADA," said Jeffrey Brewer, CEO of Bigfoot Biomedical.
  • Bigfoot will disclose additional information about the presentation aligned with the American Diabetes Association's abstract embargo policies.
  • Bigfoot Biomedical was founded by a team of people with personal connections to Type 1 and Type 2 diabetes.

Bigfoot Biomedical® Strengthens Leadership Team with Experienced Chief Commercial Officer

Retrieved on: 
Thursday, May 26, 2022
Health, Diabetes, Diabetes, Bigfoot, Lilly, Rainville, Bigfoot Biomedical, Eli Lilly and Company, Patient, NASDAQ, Solution, Marketing, MDI, Industry, Biomedicine, Instagram, Insulin, LLY, Adoption, LinkedIn, Twitter, Growth, NYSE, CEO, Pharmaceutical industry, Facebook

Bigfoot Biomedical, a mission-driven company dedicated to supporting better health outcomes for people with insulin-requiring diabetes, announced today that Matt Rainville has been appointed chief commercial officer.

Key Points: 
  • Bigfoot Biomedical, a mission-driven company dedicated to supporting better health outcomes for people with insulin-requiring diabetes, announced today that Matt Rainville has been appointed chief commercial officer.
  • Hiring a chief commercial officer is a crucial step for our business as we expand access to our Bigfoot Unity System and further develop our pipeline, said Jeffrey Brewer, CEO of Bigfoot Biomedical.
  • We are thrilled to welcome Matt to the Bigfoot leadership team and are eager to harness his passion for improving care for people with diabetes.
  • Bigfoot Biomedical was founded by a team of people with personal connections to Type 1 and Type 2 diabetes.